Dominique Meyer

Q: What Schools Are Affiliated With Dominique Meyer

Dominique Meyer is affiliated with the following schools: University of Vermont, KU Leuven, University of Michigan, University of Bern

Dominique Meyer's AcademicInfluence.com Rankings

Dominique Meyer

Philosophy

#8358

World Rank

#11717

Historical Rank

Ontology

#97

World Rank

#108

Historical Rank

Logic

#5391

World Rank

#6785

Historical Rank

philosophy Degrees

Dominique Meyer

Biology

#11302

World Rank

#14688

Historical Rank

Molecular Biology

#1731

World Rank

#1760

Historical Rank

Biochemistry

#1858

World Rank

#1998

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Dominique Meyer's Degrees

Doctorate Medicine Stanford University

Why Is Dominique Meyer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dominique Meyer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor (2006) (1060)
Platelet Factor 4 Complexed to Heparin Is the Target for Antibodies Generated in Heparin-Induced Thrombocytopenia (1992) (720)
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD) (2006) (509)
Impact, Diagnosis and Treatment of von Willebrand Disease (2000) (497)
Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. (2001) (414)
Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). (2007) (384)
Acquired von Willebrand Syndrome: Data from an International Registry (2000) (346)
Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. (1998) (321)
Thrombotic risk factors in pulmonary hypertension. (2000) (284)
Antibodies to Macromolecular Platelet Factor 4-Heparin Complexes in Heparin-induced Thrombocytopenia: a Study of 44 Cases (1995) (282)
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. (2007) (264)
New variant of von Willebrand disease with defective binding to factor VIII. (1989) (237)
Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. (1996) (226)
Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. (1982) (210)
Platelet Membrane Glycoproteins Implicated in Ristocetin-Induced Aggregation (1975) (208)
Pathogenicity of IgA and/or IgM antibodies to heparin–PF4 complexes in patients with heparin‐induced thrombocytopenia (1996) (201)
Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. (1996) (195)
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. (2008) (192)
Human Gene Mutation (1994) (178)
Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. (2001) (171)
Structure-function relationship of human von Willebrand factor. (1987) (166)
Shear Rate Dependent Inhibition of Platelet Adhesion and Aggregation on Collagenous Surfaces by Antibodies to Human Factor VIII/von Willebrand Factor (1980) (160)
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD) (2008) (160)
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). (2008) (159)
Ser968Thr Mutation within the A3 Domain of Von Willebrand Factor (VWF) in Two Related Patients Leads to a Defective Binding of VWF to Collagen (2001) (147)
Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. (1985) (142)
von Willebrand factor: structure and function. (1991) (139)
Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease. (1980) (131)
Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. (1997) (124)
International Survey of Patients with von Willebrand Disease and Angiodysplasia (1993) (122)
Circulating Procoagulant Microparticles in Women with Unexplained Pregnancy Loss: a New Insight (2001) (120)
Generation of antibodies to heparin‐PF4 complexes without thrombocytopenia in patients treated with unfractionated or low‐molecular‐weight heparin (1996) (120)
An Experimental Model to Study the in Vivo Survival of von Willebrand Factor (2004) (119)
Gene Defects in 150 Unrelated French Cases with Type 2 von Willebrand Disease: from the Patient to the Gene (1997) (119)
Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw–Schulman syndrome) (2004) (118)
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD (2006) (117)
Estimation of the von Willebrand Factor-cleaving Protease in Plasma Using Monoclonal Antibodies to vWF (1999) (117)
Acquired von Willebrand Syndrome: from Pathophysiology to Management (2000) (114)
Haemophilia B Due to a De Novo Insertion of a Human-Specific Alu Subfamily Member within the Coding Region of the Factor IX Gene (1993) (112)
Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. (2001) (109)
Increased metastatic potential of tumor cells in von Willebrand factor‐deficient mice (2006) (108)
von Willebrand Factor: Structure and Function (1993) (100)
Willebrand Factor and Ristocetin II. RELATIONSHIP BETWEEN WILLEBRAND FACTOR, WILLEBRAND ANTIGEN AND FACTOR‐VIII ACTIVITY (1974) (100)
Mapping of distinct von Willebrand factor domains interacting with platelet GPIb and GPIIb/IIIa and with collagen using monoclonal antibodies. (1986) (98)
ROLE OF VON WILLEBRAND FACTOR IN PLATELET ADHESION TO THE SUBENDOTHELIUM (1983) (98)
Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease. (1983) (97)
Localization of a factor VIII binding domain on a 34 kilodalton fragment of the N-terminal portion of von Willebrand factor. (1987) (95)
Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. (2003) (92)
Ets transcription factors bind and transactivate the core promoter of the von Willebrand factor gene (1997) (92)
Congenital bleeding disorders with long bleeding time and normal platelet count. II. Von Willebrand's disease (report of thirty-seven patients). (1968) (90)
Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. (2006) (88)
Ristocetin and Botrocetin Involve Two Distinct Domains of von Willebrand Factor for Binding to Platelet Membrane Glycoprotein lb (1990) (86)
Thrombotic thrombocytopenic purpura and its diagnosis (2005) (86)
Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. (1993) (83)
A New Functional Assay for Human Protein S Activity Using Activated Factor Vas Substrate (1989) (83)
Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates (1999) (82)
A new method for the estimation of protein C by ELISA. (1984) (80)
Cross-reacting material in congenital factor VIII deficiencies (Haemophilia A and von Willebrand's disease) (1972) (79)
Localization of von Willebrand Factor-binding Sites for Platelet Glycoprotein Ib and Botrocetin by Charged-to-Alanine Scanning Mutagenesis* (2000) (78)
Replacement Therapy with Virus—Inactivated Plasma Concentrates in von Willebrand Disease (1992) (77)
Differential distribution of von Willebrand factor in endothelial cells. Comparison between normal pigs and pigs with von Willebrand disease. (1987) (77)
Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen. (1993) (76)
Willebrand Factor and Ristocetin I. MECHANISM OF RISTOCETIN‐INDUCED PLATELET AGGREGATION (1974) (73)
Inhibition of von Willebrand factor–platelet interaction by fibrinogen (1984) (70)
von Willebrand factor-mediated platelet adhesion to collagen involves platelet membrane glycoprotein IIb-IIIa as well as glycoprotein Ib. (1988) (69)
Shear rate-dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and hemophilia A. (1992) (69)
Factor VIII Binding Assay of von Willebrand Factor and the Diagnosis of Type 2N von Willebrand Disease -Results of an International Survey (1996) (68)
Experimental Model for von Willebrand's Disease (1973) (66)
Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study (2009) (66)
Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1VWD) (2007) (64)
Hybridoma antibodies to human von Willebrand factor (1984) (60)
The binding domain of von Willebrand factor to sulfatides is distinct from those interacting with glycoprotein Ib, heparin, and collagen and resides between amino acid residues Leu 512 and Lys 673. (1991) (59)
Platelet von Willebrand factor: evidence for its involvement in platelet adhesion to collagen. (1987) (59)
Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. (2004) (58)
Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension (2000) (57)
Conformational changes in the D' domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment. (2000) (57)
Treatment of Severe Venous Thrombo-Embolism with Intravenous Hirudin (HBW 023): An Open Pilot Study (1993) (56)
Role of Platelet Membrane Glycoproteins and Von Willebrand Factor in Adhesion of Platelets to Subendothelium and Collagen (1987) (56)
Selective Absence of Large Forms of Factor VIII/Von Willebrand Factor in Acouired Von Willebrano’s Syndrome. Response to Transfusion (1979) (56)
Expression of von Willebrand factor in porcine vessels: Heterogeneity at the level of von Willebrand factor mRNA (1989) (56)
Oct-1 is involved in the transcriptional repression of the von willebrand factor gene promoter. (1998) (53)
Annexin V delays apoptosis while exerting an external constraint preventing the release of CD4+ and PrPc+ membrane particles in a human T lymphocyte model. (1999) (52)
Homozygous Variant of Antithrombin III : AT III Fontainebleau (1986) (52)
Heterogeneity of von Willebrand's disease: Study of 40 Iranian Cases (1977) (52)
New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form (1994) (51)
Mediation of platelet adhesion to fibrillar collagen in flowing blood by a proteolytic fragment of human von Willebrand factor. (1986) (51)
Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib. (1999) (50)
Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. (2001) (50)
Protein C, protein S and antithrombin III in children with portal vein obstruction. (1997) (50)
Precipitating antibodies in von Willebrand's disease (1976) (49)
The factor VIII abnormality in severe von Willebrand's disease. (1979) (48)
Von Willebrand factor has more than one binding site for platelets. (1984) (47)
Standard Nomenclature for Factor VIII and von Willebrand Factor: A Recommendation by the International Committee on Thrombosis and Haemostasis (1985) (45)
Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII‐binding capacity (2003) (44)
Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. (2006) (44)
Scott syndrome: an inherited defect of the procoagulant activity of platelets. (1997) (44)
The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease (1994) (43)
Significance of capacitative Ca2+ entry in the regulation of phosphatidylserine expression at the surface of stimulated cells. (1999) (43)
Another Protein S Functional Assay Is Sensitive to Resistance to Activated Protein C (1994) (43)
Role of von Willebrand factor associated to extracellular matrices in platelet adhesion. (1991) (43)
Duplication of a methionine within the glycoprotein Ib binding domain of von Willebrand factor detected by denaturing gradient gel electrophoresis in a patient with type IIB von Willebrand disease. (1991) (43)
"Variants" of von Willebrand's disease. Demonstration of a decreased antigenic reactivity by immunoradiometric assay. (1978) (42)
The impact of bleeding history, von Willebrand factor and PFA–100® on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM‐1VWD (2010) (42)
Continuous Infusion of Prostacyclin Decreases Plasma Levels of t-PA and PAI-1 in Primary Pulmonary Hypertension (1995) (42)
Familial incidence of precipitating antibodies in von Willebrand's disease: a study of four cases. (1979) (42)
Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease. (1992) (41)
Epitope Mapping of Inhibitory Monoclonal Antibodies to Human von Willebrand Factor by Using Recombinant cDNA Libraries (1994) (41)
Localization of a collagen-interactive domain of human von Willebrand factor between amino acid residues Gly 911 and Glu 1,365 (1987) (41)
Immunoradiometric Assay of Factor VIII: Coagulant Antigen using Four Human Antibodies. Study of 27 Cases of Haemophilia A (1981) (41)
Comparison of Functional Assays for Protein S: European Collaborative Study of Patients with Congenital and Acquired Deficiency (1993) (41)
Solid-phase von Willebrand factor contains a conformationally active RGD motif that mediates endothelial cell adhesion through the alpha v beta 3 receptor. (1993) (40)
Multi‐therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease (2003) (39)
Hybridoma antibodies to human von Willebrand factor (1984) (39)
Platelet aggregation induced by a monoclonal antibody to the A1 domain of von Willebrand factor. (1998) (39)
Production in Escherichia coli of a biologically active subfragment of von Willebrand factor corresponding to the platelet glycoprotein Ib, collagen and heparin binding domains. (1989) (38)
Detection of a molecular defect in 40 of 44 patients with haemophilia B by PCR and denaturing gradient gel electrophoresis (1993) (38)
Aurin Tricarboxylic Acid Inhibits Platelet Adhesion to Collagen by Binding to the 509-695 Disulphide Loop of von Willebrand Factor and Competing with Glycoprotein Ib (1992) (37)
Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B. (2001) (37)
Multicenter Comparison of Five Functional and Two Immunological Assays for Protein C (1987) (37)
Localization of a collagen-interactive domain of human von Willebrand factor between amino acid residues Gly 911 and Glu 1,365. (1987) (36)
Investigation of a case of subtype IIC von Willebrand disease: Characterization of the variability of this subtype (1986) (36)
Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide (2006) (36)
An Enzyme Immunoassay (ELISA) for the Quantitation of Human Factor VII (1986) (36)
von Willebrand factor and platelet function. (1989) (36)
Optimization of the transfection of human endothelial cells by electroporation. (1994) (35)
Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand disease. (1994) (35)
A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the Al disulphide loop (Cys509‐Cys695) discriminates between type 2A and type 2B von Willebrand disease (1995) (35)
The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. (2001) (34)
Molecular Genetics of Type 2 von Willebrand Disease (2002) (34)
Characterization of human anti-factor VIII antibodies purified by immune complex formation. (1976) (33)
Prevalence of antiphospholipid‐related antibodies in unselected patients with history of venous thrombosis (1998) (33)
Von Willebrand factor and platelet adhesiveness (1970) (32)
Binding of human von Willebrand factor to collagen and to collagen-stimulated platelets. (1987) (32)
The role of the 5'-flanking region in the cell-specific transcription of the human von Willebrand factor gene. (1993) (32)
Identification of the Regulatory Elements of the Human von Willebrand Factor for Binding to Platelet GPIb (2002) (31)
Biological findings in Von Willebrand's pedigrees: implications for inheritance (1967) (31)
A simple and efficient method for isolating high molecular weight DNA from mammalian sperm. (1988) (31)
A conserved epitope on several human vitamin K-dependent proteins. Location of the antigenic site and influence of metal ions on antibody binding. (1988) (30)
A New Automated Method for von Willebrand Factor Antigen Measurement Using Latex Particles (1999) (30)
Laboratory diagnosis of von Willebrand disease (1998) (30)
A stop codon in a patient with severe type III von Willebrand disease. (1991) (30)
Comparison of the primary structure of the functional domains of human and porcine von Willebrand factor that mediate platelet adhesion. (1992) (29)
Oct-1 Is Involved in the Transcriptional Repression of the von Willebrand Factor Gene Promoter (1998) (29)
Relative importance of the glycoprotein Ib-binding domain and the RGD sequence of von Willebrand factor for its interaction with endothelial cells. (1997) (29)
Immunological Evidence that Human Factor VIII is Composed of Two Linked Moieties (1977) (29)
Influence of mutations and size of multimers in type II von Willebrand disease upon the function of von Willebrand factor. (1994) (28)
Antithrombin Milano: a new variant with monomeric and dimeric inactive antithrombin III. (1985) (28)
Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation. (2000) (27)
SYNTHETIC RGD-CONTAINING PEPTIDES OF VON WILLEBRAND FACTOR INHIBIT PLATELET ADHESION TO COLLAGEN (1987) (27)
Abnormal factor IX during anticoagulant treatment. (1970) (26)
Carrier Detection in Severe (Type III) von Willebrand Disease Using Two Intragenic Restriction Fragment Length Polymorphisms (1988) (26)
Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. (2010) (26)
Heparin-Dependent Antigens in Heparin-Induced Thrombocytopenia (2003) (26)
Multicenter Comparison of von Willebrand Factor Multimer Sizing Techniques (1985) (26)
Functional assay of protein S in 70 patients with congenital and acquired disorders (1991) (25)
Fine epitope mapping of monoclonal antibodies to the NH2‐terminal part of von Willebrand factor (vWF) by using recombinant and synthetic peptides: interest for the localization of the factor VIII binding domain (1994) (25)
Two clusters of charged residues located in the electropositive face of the von Willebrand factor A1 domain are essential for heparin binding. (2002) (25)
Characterization of Recombinant von Willebrand Factors Mutated on Cysteine 509 or 695 (1996) (25)
Effect of plasmid size on transformation efficiency by electroporation of Escherichia coli DH5 alpha. (1994) (23)
Apoptosis in Vascular Disease (1999) (23)
Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques. (2007) (23)
Cross-reacting material in genetic variants of haemophilia B (1972) (23)
The biological basis of immune heparin-induced thrombocytopenia. (1998) (23)
Fast and Efficient Mutation Detection Method Using Multiplex PCR and Cycle Sequencing (2000) (22)
Somatic mosaicism and compound heterozygosity in female hemophilia B. (2000) (22)
Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion (2006) (22)
Structure-Function Relationship of the A1 Domain of von Willebrand Factor (1995) (22)
Abnormality of glycoprotein Ib in two cases of "pseudo"-von Willebrand's disease. (1985) (21)
Problems in the detection of carriers of haemophilia A. (1975) (20)
Binding of Heparin Fractions to von Willebrand Factor: Effect of Molecular Weight and Affinity for Antithrombin III (1994) (20)
Processing and Characterization of Recombinant von Willebrand Factor Expressed in Different Cell Types Using a Vaccinia Virus Vector (1992) (20)
WILLEBRAND-FACTOR ACTIVITY AND ANTIGEN IN VON WILLEBRAND'S DISEASE (1974) (20)
Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely. (1992) (20)
A patient with type 2N von Willebrand disease is heterozygous for a new mutation: Gly22Glu. Demonstration of a defective expression of the second allele by the use of monoclonal antibodies. (1997) (20)
Fluid-phase immunoradiometric assay for the detection of qualitative abnormalities of factor VIII/von Willebrand factor in variants of von Willebrand's disease. (1979) (20)
Another link between phospholipid transmembrane migration and ABC transporter gene family, inferred from a rare inherited disorder of phosphatidylserine externalization. (1997) (20)
Factor VIII and IX Variants. Relationship between Haemophilia BM and Haemophilia B+ (1971) (20)
Functional Analysis of the Arg91GIn Substitution in the Factor VIII Binding Domain of von Willebrand Factor Demonstrates Variable Phenotypic Expression (1993) (19)
Molecular study of von Willebrand disease: identification of potential mutations in patients with type IIA and type IIB (1992) (19)
A comparison between two semi‐quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease (2011) (19)
Heterogeneity in Biological Activity of Human Factor VIII Antibodies (1975) (18)
Comparison of the 5'-flanking sequences of the human and bovine von Willebrand factor-encoding genes reveals alternation of highly homologous domains with species-specific Alu-type repeats. (1995) (18)
Molecular genetics of von Willebrand disease. (1998) (18)
The human gene for von Willebrand factor. Identification of repetitive Alu sequences 5' to the transcription initiation site. (1988) (18)
Complete Defect in vWF-cleaving Protease Activity Associated with Increased Shear-induced Platelet Aggregation in Thrombotic Microangiopathy (2002) (18)
A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease (2003) (18)
Identification of a CpG mutation in the coagulation factor‐IX gene by analysis of amplified DNA sequences (1988) (18)
Analysis of von Willebrand factor mRNA from the lung of pigs with severe von Willebrand disease by using a human cDNA probe. (1988) (18)
Role of von Willebrand Factor in Platelet Vessel‐Wall Interactions (1987) (17)
A second Xba I polymorphic site within the human von Willebrand factor (vWF) gene. (1987) (17)
Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease (2006) (17)
Mapping and Functional Studies of Two Alloantibodies Developed in Patients with Type 3 von Willebrand Disease (2000) (17)
Clinical applications of a direct assay of free protein S antigen using monoclonal antibodies. A study of 59 cases (1994) (17)
Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples (2006) (17)
Identification of a New Type 2M von Willebrand Disease Mutation also at Position 1324 of von Willebrand Factor (2002) (16)
Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome. (2001) (16)
First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene (2004) (16)
Shear Rate Dependence of Platelet Adhesion to Collagenous Surfaces in Willebrand Factor-Depleted Blood (1977) (16)
Case Report: Prothrombin 20210G/A Mutation in Two Patients with Mesenteric Ischemia (1999) (16)
von Willebrand Factor Ristocetin Cofactor Activity Correlates with Platelet Function in a High Shear Stress System (2000) (16)
Abnormal Proteolytic Processing of von Willebrand Factor Arg611 Cys and Arg 611 His (1997) (16)
Localization within the 106 N-terminal amino acids of von Willebrand factor (vWF) of the epitope corresponding to a monoclonal antibody which inhibits vWF binding to factor VIII. (1989) (15)
Registry of Monoclonal Antibodies to Factor VIII and von Willebrand Factor (1985) (15)
von Willebrand factor and platelet interactions with the vessel wall. (1991) (15)
Familial Variant of Antithrombin III (AT III Bligny, 47Arg to His) Associated with Protein C Deficiency (1990) (15)
Familial Type I Protein S Deficiency Associated with Severe Venous Thrombosis - A Study of Five Cases (1988) (15)
New Assay for Measuring Binding of Platelet Glycoprotein IIb/IIIa to Unpurified von Willebrand Factor (1999) (14)
Heparin-induced thrombocytopenia: diagnostic tests and biological mechanisms. (1998) (14)
Assessment of the Expression of Candidate Human Plasma Membrane Phospholipid Scramblase in Scott Syndrome Cells (1999) (13)
6 Von Willebrand factor and platelet function (1989) (13)
Primary structure of the factor VIII binding domain of human, porcine and rabbit von Willebrand factor. (1993) (13)
Isolation of Human Antibodies to Factor VIII (1978) (12)
Somatic mosaicism and compound heterozygosity in female hemophilia B (2000) (12)
Expression of two type 2N von Willebrand disease mutations identified in exon 18 of von Willebrand factor gene (2004) (12)
Comparison of Tryptic Fragments of von Willebrand Factor Involved in Binding to Thrombin-Activated Platelets with Fragments Involved in Ristocetin-Induced Binding and Binding to Collagen (1986) (12)
Interaction of Ristocetin and von Willebrand Factor (1976) (11)
Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension (2002) (11)
Willebrand factor: immunological and biological study. (1973) (11)
Abnormality of the N-Terminal Portion of von Willebrand Factor in Type IIA and IIC von Willebrand Disease (1988) (11)
Epitope mapping by cDNA expression of a monoclonal antibody which inhibits the binding of von Willebrand factor to platelet glycoprotein IIb/IIIa. (1992) (11)
Antibody to human factor VIII/von Willebrand factor inhibits collagen-induced platelet aggregation and release. (1980) (11)
2 Molecular basis of von Willebrand disease (1996) (11)
Protein C, protein S and antithrombin III in children with portal vein obstruction (1997) (10)
Incidence of immune responses following 102 infusions of autoplex in 18 hemophilic patients with antibody to factor VIII. (1984) (10)
Carrier detection and prenatal diagnosis in 98 families of haemophilia A by linkage analysis and direct detection of mutations (1991) (10)
Modulation by heparin of the interaction of the A1 domain of Von Willebrand factor with glycoprotein Ib. (1999) (10)
Identification of genes involved in Ca2+ ionophore A23187-mediated apoptosis and demonstration of a high susceptibility for transcriptional repression of cell cycle genes in B lymphoblasts from a patient with Scott syndrome (2005) (9)
A Taq I polymorphism in the 5' region of the von Willebrand factor (vWF) gene. (1988) (9)
Desmopressin, an unexpected link between nocturnal enuresis and inherited thrombotic thrombocytopenic purpura (Upshaw‐Schulman syndrome) (2006) (9)
LETTERS TO THE EDITOR: Graduated compression stockings for the prevention of venous thromboembolism in surgical patients in the age of low molecular weight heparins (2005) (9)
Functional characterization of bovine von Willebrand factor gene promoter in bovine endothelial cells demonstrates species-specific properties. (1997) (9)
A directed search for mutations in hemophilia A using restriction enzyme analysis and denaturing gradient gel electrophoresis. A study of seven exons in the factor VIII gene of 170 cases. (1992) (9)
Primary structure of the propeptide and factor VIII-binding domain of bovine von Willebrand factor. (1997) (9)
Clinical, Laboratory, and Molecular Markers of Type 2 von Willebrand Disease (2011) (8)
La maladie de Willebrand: du diagnostic au traitement (1995) (8)
Preparation of factor-VIII-depleted plasma with antibodies and its use for the assay of factor VIII. (1990) (8)
Haemophilia A in a Female: Study of a Family Using Intragenic and Extragenic Restriction Site Polymorphisms (1988) (8)
Structure - function relationship of factor VIII/von Willebrand factor. Application to the study of variant von Willebrand's disease and cryosupernatant prepared from normal plasma. (1980) (8)
Impaired Prothrombin Consumption in Bernard-Soulier Syndrome Is Corrected In Vitro by Human Factor VIII (1997) (8)
Abnormal antigenic reactivity of factor VIII/von Willebrand factor subunit in variants of von Willebrand's disease. (1982) (8)
Ca2+ ionophores trigger membrane remodeling without a need for store-operated Ca2+ entry. (2005) (8)
HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Conformational Changes in the A 3 Domain of von Willebrand Factor Modulate the Interaction of the A 1 Domain With Platelet Glycoprotein Ib (1999) (7)
Report of the Subcommittee on Factor VIII Activities (1980) (7)
Von Willebrand Factor and the vascular extracellular matrix (1994) (7)
Selective inactivation of Von Willebrand factor binding to glycoprotein IIb/IIIa and to inhibitor monoclonal antibody 9 by site-directed mutagenesis. (2001) (6)
Comparative studies of available ristocetins: proteolytic activity and effect on platelets. (1975) (6)
von Willebrand factor collagen binding assay with a commercial kit using type III collagen in von Willebrand disease type 2 (2007) (6)
A novel case of compound heterozygosity with “Normandy”/type I von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWD (1994) (6)
LOCALIZATION OF A FACTOR VIII BINDING DOMAIN ON THE N-TERMINAL PORTION (FRAGMENT SpIII) OF VON WILLEBRAND FACTOR (1987) (6)
Maladie de Willebrand. (1989) (6)
Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling (1993) (5)
Molecular basis of von Willebrand disease. (1995) (5)
Precipitating anti‐VIII:C antibodies in two patients with haemophilia A (1982) (5)
Purpura thrombotique thrombocytopénique par déficit héréditaire en ADAMTS13 (syndrome d’Upshaw-Schulman) : actualités et perspectives (2005) (5)
Arg578Gln mutations in the von Willebrand factor gene in three unrelated cases of type IIB von Willebrand disease. (1993) (5)
Molecular Biology of Factor VIII/von Willebrand Factor (1978) (4)
Prenatal diagnosis in type IIA von Willebrand disease. (1990) (4)
Report of the Working Party on Factor VIII Related Antigens (1980) (4)
Increased Levels of Hemostatic Proteins are Independent of Inflammation in Glycogen Storage Disease Type Ia (2003) (4)
Mono clonal antibodies specific for factor viii from cellular hybrids (1980) (4)
Requirement of prestimulated THP‐1 monocytic cells for endothelial cell activation. Involvement of TNFα (1997) (4)
Purification and Further Characterization of Antithrombin III Milano: Lack of Reactivity with Thrombin (1987) (3)
Physiopathologie du purpura thrombotique thrombocytopénique : actualités et perspectives (2002) (3)
Interaction of von Willebrand factor with platelets activated by thrombin or a synthetic 7-amino acid peptide derived from the cleaved thrombin receptor. (1994) (3)
Influence of high ionic strength buffers on factor VIII/von Willebrand factor from different species. (1978) (3)
Recurrent Thromboembolism in Two Unrelated Patients with Double Heterozygosity for Factor V R506Q and Factor II 20210G/A Mutations (1998) (3)
Von Willebrand Factor In Platelet Interaction With Subendothelium (1981) (3)
Mono clonal antibodies to human von willebrand factor role of intra molecular loci in mediation of platelet adhesion to the subendothelium (1983) (3)
Defect of Heparin Binding in Plasma and Recombinant von Willebrand Factor with Type 2 von Willebrand Disease Mutations (2001) (3)
Cyclic adenosine monophosphate‐dependent mechanisms induce von Willebrand factor expression in the Dami megakaryoblastic cell line (1995) (3)
Monoclonal Antibodies As Probes Of Factor VIII/Von Willebrand Factor (1981) (3)
[von Willebrand disease]. (1989) (3)
[Von Willebrand disease: from diagnosis to treatment]. (2005) (2)
Interference of activated factor VII in apoptosis of erytholeukemic K562 cells. (2002) (2)
Role of cp iib iiia as well as gpi b in von willebrand factor mediated platelet adhesion to collagen (1986) (2)
Expression in Escherichia coli of a recombinant fragment (Ile 914‐Leu 1364) of human von Willebrand factor containing a collagen binding domain (1990) (2)
von Willebrand factor: a target for inhibition of thrombosis. (1993) (2)
Ex vivo experimental thrombosis in variants of von Willebrand disease. (1993) (2)
Markers of endothelial involvement in chronic pulmonary hypertension (1994) (2)
The spectrum of von Willebrand's disease. (1979) (2)
[Epsilon aminocaproic acid and hematurias in hemophiliacs. 3 cases of transient unilateral renal obstruction]. (1966) (2)
[Physiology of hemostasis. 3. Primary hemostasis]. (1970) (2)
von Willebrand factor binding to heparin in various types of von Willebrand disease. (2000) (2)
[Von Willebrand factor and platelet adhesion to the subendothelium of the vascular wall]. (1982) (2)
[Hemophilia. Variants of factor 8 and IX]. (1970) (1)
Rebuttal to the Letter to the Editor by Dr. G. Castaman et al. (1994) (1)
[Factor VIII (anti-hemophilic A factor). Biology, physiology, pathology and genetics]. (1972) (1)
Reduced Polymerization of Factor VIII/Von Willebrano Factor in Variants of Willebrand’s Disease (1979) (1)
[Diagnosis and treatment of Willebrand's disease]. (1969) (1)
[Physiology of hemostasis. I. Megakaryocytes and platelets]. (1968) (1)
Dissociation of “Factor VIII Complex” in Various Animal Species. (1975) (1)
[Evaluation of a new automated method for von Willebrand factor antigen measurement: the STA-Liatest vWF]. (1999) (1)
Platelet Membrane Glycoproteins and their Possible Relationship to the ADP Mechanism of Platelet Aggregation (1975) (1)
Modern methods for the preparation of factor VIII using monoclonal antibodies (1987) (1)
Heterozygosity and Homozygosity in von Willebrand’s Disease : A Study of 108 Cases (1977) (1)
[Inhibition of thrombus formation by anti-Willebrand monoclonal antibodies in the guinea pig]. (1999) (1)
is an inherited disorder of procoagulant phosphatidylserine and hemorrhagic complications, Scott syndrome, characterized by impaired transmembrane migration (2011) (1)
Von Willebrand Disease: Biological Diagnosis (2007) (1)
[Assay of products of fibrin and fibrinogen degradation in disseminated intravascular coagulations. Evaluation of a new technique]. (1995) (1)
European Study MCMDM-1VWD phenotype in type 1 von Willebrand disease (VWD): results from the Response to desmopressin is influenced by the genotype and (2013) (1)
Incidence of immune responses following 102 infusions of autoplex in 18 hemophilic patients with antibody to factor VIII (1984) (1)
Diagnostic biologique de la maladie de Willebrand (1997) (1)
Study of Human Factor IX Variants with an Immunoadsorption Technique (1975) (1)
Synthetic RGDS-Containing Peptides of von Willebrand Factor Inhibit Platelet Adhesion to Collagen (1990) (0)
[Ocular hemorrhages and capillary fragility]. (1967) (0)
Scientific Report of the Registry on Acquired von Willebrand Syndrome : Recommendations for Diagnosis and Management (2000) (0)
Influence of continuous infusion of prostacyclin on plasma levels of t-PA, PAI-1 and vWF in primary pulmonary hypertension (1994) (0)
Diagnosis and treatment of von Willebrand disease (1995) (0)
[Physiology of hemostasis. II. Fibrinolysis]. (1969) (0)
[Von Willebrand's syndrome (author's transl)]. (1977) (0)
ADAMTS13 activity a first episode of thrombotic microangiopathy with undetectable and inhibitory effect) in a cohort of 35 adult French patients undergoing Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, (2013) (0)
Abstract (2003) (0)
ABNORMALITY OF THE N-TERMINAL PORTION OF VON WILLEBRAND FACTOR (FRAGMENT Sp III ) IN TYPE IIA AND IIC VON WILLEBRAND DISEASE (1987) (0)
[Electrophoretic migration (on cellulose acetate) of blood coagulation factors. Application to pathology]. (1969) (0)
[Current concepts on Willebrand's disease]. (1968) (0)
von Willebrand factor proteolysis and thrombotic thrombocytopenic purpura (2001) (0)
Syndrome primaire des antiphospholipides (SAPL-1)avec anticorps antiprotéase du facteur de von Willebrand (2003) (0)
proteolytic fragment of human von Willebrand factor Mediation of platelet adhesion to fibrillar collagen in flowing blood by a (2011) (0)
FAMILIAL TYPE I PROTEIN S DEFICIENCY ASSOCIATED WITH SEVERE VENOUS THROMBOSIS. A STUDY OF FIVE CASES (1987) (0)
Problems inthedetection ofcarriers of haemophilia A (1975) (0)
[HEMOSTASIS AND COAGULATION]. (1964) (0)
[Electrophoretic detection of anantihemophilic factor a (factor VIII) on cellulose acetate]. (1968) (0)
VON WILLEBRAND FACTOR mRNA IS SEVERELY REDUCED IN PIGS WITH HOMOZYGOUS VON WILLEBRAND DISEASE (1987) (0)
Phospholipid-binding antibodies and thrombosis. Diagnostica Stago International Symposium, Paris, 14 May 1993. (1993) (0)
Letter: Willebrand-factor activity and antigen in von Willebrand's disease. (1974) (0)
and hemophilia A nonanticoagulated blood from patients with von Willebrand disease Shear rate-dependent impairment of thrombus growth on collagen in (2011) (0)
Generation of von Willebrand factor epitope libraries expressed in E. coli. (2002) (0)
Monoclonal Antibodies to Human von Willebrand Factor Study of its Structure-Function Relationship (1985) (0)
factor between amino acid residues Gly 911 and Glu 1,365 Localization of a collagen-interactive domain of human von Willebrand (2011) (0)
Thrombotic thrombocytopenic purpura related to an inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): update and perspectives (2005) (0)
2.P.314 Platelet aggregation induced by a monoclonal antibody to von Willebrand Factor (1997) (0)
Letter in response to the article “Guidance on the diagnosis and management of platelet‐type von Willebrand disease: A communication from the Platelet Physiology Subcommittee of the ISTH” (2021) (0)
Reduced Antigenic Reactivity in “Variants” of von Willebrand’s Disease (1977) (0)
[Biological diagnosis of Willebrand disease]. (1997) (0)
Homozygous Variant of Antithrombin lll : AT lll (2018) (0)
27 PROTEIN C (PC), PROTEIN S (PS) AND ANTITHROMBIN III (ATIII) IN CHILDREN WITH PORTAL VEIN OBSTRUCTION (1995) (0)
Role of PF4 in heparin-induced thrombocytopenia (1995) (0)
Biological changes following infusion of recombinant hirudin (HBW 023) in 10 patients with severe thromboembolism (1992) (0)
Particles in a Human T Lymphocyte Model Membranec + and PrP + Release of CD 4 an External Constraint Preventing the Annexin V Delays Apoptosis While Exerting (1999) (0)
severe thrombocytopenia Impaired megakaryocytopoiesis in type 2B von Willebrand disease with (2011) (0)
von Willebrand factor fragments. (1991) (0)
STRUCTURE AND FUNCTION OF von WILLEBRAND FACTOR (1993) (0)
Detection by denaturing gradient gel electrophoresis of an Arg1689Cys mutation in a Chinese patient with mild hemophilia A. (1997) (0)
[Platelet adhesiveness to glass in Willebrand's disease: application to genetic study]. (1968) (0)
Multicenter comparison of von uuillebrand Factor Multimer Sizing Techniques* Report of the Factor vlll and von Wllebrand Factor Subcommittee (2018) (0)
[Surgery in von Willebrand's disease. (A propos of 3 personal studies)]. (1969) (0)
Fluid-Phase Immunoradiometric Assay of F. VIII/WF Demonstrating Abnormal Antigenic Reactivity in Variants of Von Willebrand’s Disease (1979) (0)
Pathophysiology of thrombotic thrombocytopenic purpura: update and perspectives (2002) (0)
Current Knowledge of the AHF-Like Antigen (1975) (0)
Antibodies To F.VIII/vWF Subunit And Conformational Antigenic Determinants. Demonstration Of Distinct Abnormalities In Variants Of vWD (1981) (0)
Associotions of von Wllebrond Foclor wilh Age, Sex ond Other Risk Foclors for Alherosclerosis (2018) (0)
H'EMOSTASE ET COAGULATION. (1964) (0)
Molecular and cellular mechanisms of heparin-induced thrombocytopenias (1996) (0)
Letter: Experimental model for von Willebrand's disease. (1973) (0)
Distinct sequences of the GPIb-binding domain of von Willebrand factor are involved in shear-induced platelet aggregation (1997) (0)
Identification of a von Willebrand factor domain interacting with the extracellular matrix of endothelial cells (1993) (0)
Biological diagnosis of von Willebrand disease (1997) (0)
A SHARED EPITOPE ON HUMAN PROTEIN C, FACTOR X, FACTOR VII, AND PROTTOBIN DEFINED BY A MONOCLONAL ANTIBODY (1987) (0)
[Criteria and limitations of the diagnosis of Willebrand's disease]. (1967) (0)
Mutation of cysteines 1157 or 1234 located within the D3 domain of Von Willebrand Factor causes intracellular retention of high molecular weight multimers (2003) (0)
Differential Reactivity of Three Specific Anti-VIII:C Antibodies in Haemophilia a Patients (1979) (0)
Isolation of Specific Homologous Antibodies to Factor VIII by Immunoadsorption (1977) (0)
PLATELETS FROM PATIENTS WITH BERNARD-SOULIER SYNDROME AND VON WILLEBRAND'S DISEASE (1976) (0)
Chapter 2B Nonenzymatic cofactors: factor VIII (1986) (0)
STRUCTURE AND FFUNCTION OF von WIFLLEBRAND FACTOR (2010) (0)
Specific Precipitating Antibodies To VIII: CAg In Two Patients With Haemophilia (1981) (0)
[Analysis of platelet functions: measurement of the adhesiveness of platelets to glass on whole blood (Salzman method)]. (1967) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dominique Meyer?

Dominique Meyer is affiliated with the following schools:

Dominique Meyer's Academic­Influence.com Rankings

Dominique Meyer's Degrees

Why Is Dominique Meyer Influential?

Dominique Meyer's Published Works

Published Works

What Schools Are Affiliated With Dominique Meyer?

Dominique Meyer's AcademicInfluence.com Rankings